TITLE

Caution urged for expectant mothers on ritonavir-boosting regimen

PUB. DATE
August 2011
SOURCE
Infectious Diseases in Children;Aug2011, Vol. 24 Issue 8, p15
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses a research study by Albane Simon and colleagues which examined the prevalence of adrenal dysfunction among infants of mothers treated with lopinavir-ritonavir and zidovudine-based regimen.
ACCESSION #
65562726

 

Related Articles

  • HIV medication linked to adrenal dysfunction in newborns of HIV-infected mothers.  // Endocrine Today;Oct2011, Vol. 9 Issue 10, p36 

    The article reports on the link between the HIV medication, protease inhibitor-ritonavir, and adrenal dysfunction in newborns of mothers who have HIV.

  • Association of Prenatal and Postnatal Exposure to Lopinavir-Ritonavir and Adrenal Dysfunction Among Uninfected Infants of HIV-Infected Mothers. Simon, Albane; Warszawski, Josiane; Kariyawasam, Dulanjalee; Le Chenadec, Jerome; Benhammou, Valerie; Czernichow, Paul; Foissac, Frantz; Laborde, Kathleen; Tréluyer, Jean-Marc; Firtion, Ghislaine; Layouni, Inès; Munzer, Martine; Bavoux, Françoise; Polak, Michel; Blanche, Stéphane // JAMA: Journal of the American Medical Association;7/6/2011, Vol. 306 Issue 1, p70 

    The article highlights the use of lopinavir-ritonavir among human immunodeficiency virus- (HIV) newborns not older than 14 days. In France, two newborns were reported to have transient elevation of 17-hydroxyprogesterone (17OHP), which prompted the release of warning for its use in premature...

  • Assessment of Lopinavir Pharmacokinetics With Respect to Developmental Changes in Infants and the Impact on Weight Band-Based Dosing. Nikanjam, M; Chadwick, E G; Robbins, B; Alvero, C; Palumbo, P; Yogev, R; Pinto, J; Hazra, R; Hughes, M L; Heckman, B E; Capparelli, E V // Clinical Pharmacology & Therapeutics;Feb2012, Vol. 91 Issue 2, p243 

    Improved antiretroviral therapies are needed for the treatment of HIV-infected infants, given the rapid progression of the disease and drug resistance resulting from perinatal exposure to antiretrovirals. We examined longitudinal pharmacokinetics (PK) data from a clinical trial of...

  • Antiretrovirals/gemfibrozil/rosuvastatin interaction.  // Reactions Weekly;8/13/2011, Issue 1364, p8 

    The article describes the case of an eldery man who developed rhabdomyolysis during treatment with lopinavir/ritonavir and tenofovir for HIV infection and gemfibrozil and rosuvastatin for dyslipidemia.

  • Lopinavir/ritonavir.  // Reactions Weekly;Nov2014, Vol. 1528 Issue 1, p137 

    The article presents case studies of two HIV-infected patients who developed symptomatic grade III hepatotoxicity after receiving double-dose lopinavir/ ritonavir tablets for at least 2 months.

  • Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers. Jackson, A. G. A.; Hill, A.; Else, L. J.; Back, D. J.; Morley, R.; Puls, R.; Amin, J.; Lin, E.; Boffito, M. // Journal of the International AIDS Society;2010 Supplement 4, Vol. 13 Issue Suppl 4, p1 

    An abstract of the article "Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers," by several authors including AGA Jackson, A Hill, and DJ Back is presented.

  • Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy. Surah, S.; Oshea, S.; Costelloe, S.; Hanlon, M.; Mullen, J.; Chrystie, I.; Taylor, G. P.; De Ruiter, A. // Journal of the International AIDS Society;2010 Supplement 4, Vol. 13 Issue Suppl 4, p1 

    An abstract of the article "Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy," by several authors including GP Taylor, M Douglas, and J Smith is presented.

  • Lacidipine/lopinavir/ritonavir/metoprolol interaction.  // Reactions Weekly;4/16/2011, Issue 1347, p26 

    The article describes the case of a 51-year-old man who developed bradycardia, hypotension and complete antrioventricular (AV) block while being treated with lacidipine, lopinavir, ritonavir and metoprolol.

  • Orlistat/lopinavir/ritonavir interaction.  // Reactions Weekly;5/7/2011, Issue 1350, p36 

    The article describes the case of a 39-year-old woman with HIV-1 infection who experienced decreased cerebrospinal fluid (CSF) lopinavir concentrations, leading to HIV-related meningo-encephalitis, during highly active anti-retroviral therapy (HAART) with lopinavir/ritonavir in addition to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics